immunocore is a privately owned biotechnology company developing innovative biological therapeutics for the treatment of a range of serious diseases. its world-leading t cell receptor technology exploits the power of the body’s own immune system to find and kill diseased cells. immunocore has established a robust technology platform which combines monoclonal t cell receptor (mtcr) targeting technology with an effector technology, anti-cd3 scfv, that catalyses the killing of the targeted diseased cells by the host’s own non-specific cytotoxic t cells. immunocore is developing a portfolio of products from the platform, called immtacs, for the treatment of cancer, chronic infectious disease and diabetes.
Company profile
Ticker
IMCR
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Bio-Techne • Sana Biotechnology • Ginkgo Bioworks • Acorda Therapeutics ...
Former names
Immunocore Ltd
SEC CIK
IMCR stock data
Latest filings (excl ownership)
6-K
Current report (foreign)
7 Nov 23
6-K
Current report (foreign)
10 Aug 23
6-K
Current report (foreign)
14 Jul 23
6-K
Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO
5 Jun 23
6-K
Current report (foreign)
16 May 23
6-K
Current report (foreign)
10 May 23
6-K
Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival
18 Apr 23
6-K
Current report (foreign)
18 Apr 23
S-8
Registration of securities for employees
6 Apr 23
6-K
Current report (foreign)
10 Mar 23
Latest ownership filings
144
Notice of proposed sale of securities
30 Nov 23
144
Notice of proposed sale of securities
16 Nov 23
144
Notice of proposed sale of securities
6 Nov 23
144
Notice of proposed sale of securities
2 Oct 23
SC 13D/A
GENERAL ATLANTIC, L.P.
18 Sep 23
144
Notice of proposed sale of securities
25 Aug 23
144
Notice of proposed sale of securities
17 Aug 23
144
Notice of proposed sale of securities
12 Jul 23
SC 13D/A
GENERAL ATLANTIC, L.P.
15 Jun 23
144
Notice of proposed sale of securities
5 Jun 23
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Institutional ownership, Q3 2023
78.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 125 |
Opened positions | 12 |
Closed positions | 9 |
Increased positions | 50 |
Reduced positions | 37 |
13F shares | Current |
---|---|
Total value | 1.90 tn |
Total shares | 39.03 mm |
Total puts | 2.90 k |
Total calls | 212.30 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
RTW Investments | 6.10 mm | $316.40 bn |
Wellington Management | 3.91 mm | $203.11 bn |
Rock Springs Capital Management | 2.94 mm | $152.78 bn |
T. Rowe Price | 2.52 mm | $131.05 bn |
Baker Bros. Advisors | 2.52 mm | $130.83 bn |
FMR | 2.14 mm | $110.87 bn |
Malin Life Sciences | 2.11 mm | $111.40 mm |
Paradigm Biocapital Advisors | 1.38 mm | $71.87 bn |
MS Morgan Stanley | 961.09 k | $49.88 bn |
General Atlantic | 950.00 k | $49.31 bn |
News
5 Analysts Have This to Say About Immunocore Hldgs
20 Nov 23
JP Morgan Reinstates Overweight on Immunocore Hldgs, Announces $60 Price Target
20 Nov 23
Immunocore Hldgs Q3 EPS $0.04 Down From $0.13 YoY, Sales $60.73M Miss $62.14M Estimate
7 Nov 23
Analyst Ratings for Immunocore Hldgs
2 Nov 23
Cantor Fitzgerald Initiates Coverage On Immunocore Hldgs with Overweight Rating
2 Nov 23
Press releases
Levicept Appoints Eliot Forster as CEO
30 Nov 23
AGC Biologics to Prepare Late Phase and Commercial Runs for Immunocore
20 Nov 23
Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update
7 Nov 23
Immunocore announces upcoming poster presentations at SITC Annual Meeting 2023 and SMR Congress 2023
1 Nov 23
Immunocore to present at upcoming investor conferences
30 Oct 23